Author: Matthew Nelson|| Date Published: August 7, 2020
An SRI International division has secured a potential seven-year, $100M contract to help a National Institutes of Health component develop methods to medical conditions caused by direct exposure or contamination from radioactive materials.
SRI Biosciences will support the National Institute of Allergy and Infectious Diseases in research and development of medical countermeasures for radiological and nuclear emergencies, the nonprofit said Wednesday.
The partnership will also explore biological dosimetry tests and advance candidate treatments for acute radiation syndromes, delayed effects from acute radiation exposure and internal radionuclide contamination.
Both NIH and NIAID have worked with SRI Biosciences to develop radiation therapies as part of a contract slated to expire this month.
Noblis MSD has won a five-year, single-award IDIQ contract to provide end-to-end engineering services for the Network Integration Engineering Facility…
The acquisition expands Empower AI’s capabilities in AI, cloud, data management and DevSecOps Highlight Technologies adds digital modernization and AI-driven…
